The Hydroponics Company Ltd's (ASX:THC) wholly owned subsidiary Canndeo Limited has made its first medicinal cannabis products available to patients in Australia.
The products have been imported from THC’s European partner Endoca and are available via the Medicinal Cannabis Medicines Portal (MCMP) website.
Pharmacies and prescribers can use the website to access THC imported Endoca products.
READ: The Hydroponics Company secures lease for cannabis growing site and off-take
THC’s CEO Ken Charteris said: “We are pleased to now be delivering high-quality medicinal cannabis products to the Australian market through MCMP having leveraged our global commercial partnerships, including Endoca and Sinapse.
“Using MCMP reduces the administrative burden on prescribing doctors and pharmacies, which is currently a key challenge for the prescribing of medicinal cannabis in Australia.
“We look forward to seeing the first patients using product supplied by THC in the coming weeks.”
Advancing medicinal cannabis strategy
Carteris added: “Bringing product to the Australian market is a key step in the execution of our medicinal cannabis strategy, with imported product to be followed by THC’s domestic production taking advantage of our industry leading pharmaceuticals manufacturing facility and significant growing capacity.”
MCMP website co-founded by Canndeo
Canndeo is a founding partner of MCMP, which was developed by Sinapse Pty Ltd, a leader in pharmaceutical IT systems.
It provides a streamlined process for medicinal cannabis prescribing and dispensing between health professionals and manufacturers of medicinal cannabis.